Dr Al-Samkari

Ayad et al. Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia. Blood 2022;140(26):2849-52. Abstract

Cuker A et al. Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States. eJHaem 2023;4(2):350-7. Abstract

Goncalves I et al. Thrombosis in patients with immune thrombocytopenia: Incidence, risk, and clinical outcomes. Res Pract Thromb Haemost 2024;8(1):102342. Abstract

Dr Bussel

Bussel J et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am Hematol 2018;93(7):921-30. Abstract

Bussel JB et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol 2019;94(5):546-53. Abstract

Kuter DJ et al. Long-term efficacy and safety with oral Bruton tyrosine kinase inhibitor rilzabrutinib in patients with immune thrombocytopenia. ISTH 2024;Abstract OC 65.1.

Prof Cooper

Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. eBioMedicine 2022;76:103820. Abstract

Kuter DJ, et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med 2022;386(15):1421-31. Abstract